Industry Insights

  1. Virtue Is Harmony: Using Lab Data Automation To Break Down The Silos In Pharma R&D
    6/7/2017

    In a scenario where manufacturing processes move to a continuous flow, analyzers are producing data simultaneously, necessitating real-time processing and cloud-based tools for data management.

  2. Prepare For An FDA Bioburden Inspection
    1/29/2018

    A former FDA Biologics License Application reviewer and inspector focusing on microbiology, shares expert tips on how to best approach a bioburden problem when an FDA inspection is imminent.

  3. With Serialization Mandate Looming, Is Your Data Management System Ready?
    5/10/2017

    In spite of the FDA’s announcement to postpone enforcement until November 2018, all other requirements of the DSCSA remain the same

  4. What You Need To Know About Continuous Processing
    2/1/2018

    There is a lot of interest around continuous biomanufacturing, but could a hybrid of batch and continuous unit operations be the best solution for your process train?

  5. Are Today’s Processes Efficient Enough For The Future Of Vaccine And Viral Vector Production?
    3/8/2018

    By recognizing the limitations of today’s production processes, the industry may be able to overcome the challenges, complexity, and high cost of manufacturing vaccines and viral vector-based therapies.

  6. How To Use QbD Software To Improve An Existing Identification Method
    11/15/2017

    What can you do when the identification method defined by the USP monograph does not provide clear guidance? The authors decided to improve the method with a Quality by Design (QbD) approach.

  7. Implications Of Inaccurate Forecasting On Biologics Manufacturing
    6/16/2016

    Inaccurate demand forecasts can have significant implications for companies developing biologics. And, it is increasingly difficult to locate capacity to respond to demand changes.

  8. Could A Fear Of QbD Slow Your Breakthrough Therapy Drug’s Speed To Market?
    8/16/2017

    As pharma continues to evolve, the drive to pursue new cutting-edge drugs will become even greater. For those companies competing to push the boundaries of innovation, a fear of implementing QbD might end up being the biggest threat in its race to the finish.

  9. WuXi Biologics Creates Next-Generation Continuous Manufacturing Platform
    12/20/2017

    Many biologics companies will partner with a contract development and manufacturing organization that can provide the required expertise and resources as well as flexibility of operations.

  10. Ozonolysis Development Solutions For Safety Studies And Scale Up
    3/29/2017

    Ozonolysis is a widely used reaction in organic synthesis. The reaction was invented by Christian Friedrich Schoenbein in 1840. Alkenes and alkynes are the most common substrates for the ozonolysis reaction. Ozonolysis was an important diagnostic tool for the determination of the position of unsaturation in unknown molecules before the invention and development of spectroscopic techniques for identification and characterization of organic molecules. The reaction was used for structure elucidation work because it provided chemists with smaller and more readily identifiable carbonyl compounds.